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Abstract 
 
Obsessive-compulsive disorder (OCD) is characterized by the presence of 
obsessions and/or compulsions. It is a leading cause of morbidity worldwide, as it can 
interfere with all aspects of life. Despite the adequate treatment trials, half of patients 
preserve residual or impairing symptoms and serotonin reuptake inhibitors (SRIs) are 
not free from adverse side effects. 
This work aims to systematically review the current evidence available 
concerning the efficacy of N-acetylcysteine (NAC) in the treatment of OCD. 
Nine articles and one poster were included in our systematic review. Three of the 
five case reports encompassed showed a marked improvement in Y-BOCS, one failed to 
prove the efficacy of NAC in the treatment of OCD and the other one reported 
contradictory results. Regarding the five randomized controlled trials (RCTs) included, 
three reported significant improvement in Y-BOCS in the NAC treated group and the 
other two showed no significant improvement. NAC has an optimal tolerability profile, 
even in higher doses, and the most frequently reported adverse events were 
gastrointestinal. 
Despite the degree of evidence being D, in our opinion the potential of NAC is 
underestimated.  
Considering its exceptional tolerability profile, the use as an add-on agent should 
be contemplated, on an ad hoc basis.  
Keywords:  N-acetylcysteine; obsessive-compulsive disorder; nutraceutical  
  
1. Introduction 
Obsessive-compulsive disorder (OCD) is characterized by the presence of 
obsessions and/or compulsions.1 Obsessions are recurrent, persistent, distressing 
thoughts, mental images, or impulses that are experienced as intrusive and unwanted. 
Patients with OCD try to neutralize the anxiety and discomfort from the obsessions with 
compulsions. Compulsions are repetitive behaviors or mental acts that a person with 
OCD feels the urge to do in response to an obsessive thought. In fact, performing 
compulsions when obsessions recur, leads to reinforcement and repetitive behavior, due 
to the transitory relief of stress.2  
OCD is a leading cause of morbidity worldwide with 1.1%–1.8% annual 
prevalence 1 and  2%–3% lifetime prevalence.3 It is a potentially disabling psychiatric 
disorder that can interfere with all aspects of life, such as work, school, and personal 
relationships. The age at onset is bimodal, with peaks in late childhood or early 
adolescence and early adulthood.4  
Converging lines of evidence link OCD to abnormalities in the orbitofrontal 
cortex (OFC), anterior cingulate cortex (ACC), striatum, and thalamus.5,6 Orbitofrontal 
cortex is functionally divided into two parts7: the lateral OFC is hyperactivated (during 
symptom provocation8,9 and proportionally to OCD symptom severity10) and the medial 
OFC is hypoactivated (inversely correlated with symptom severity).14 The dorsal 
anterior cingulate cortex (dACC) has also been implicated, proved not only by 
functional neuroimaging 11,12 and treatment studies 13, but also by the decrease in OCD 
symptoms after anterior cingulotomy.14,15 
At the neurocircuit level, a combination of neuroimaging, neuropsychological and 
treatment studies have provided substantial evidence that the pathophysiology of OCD 
entails abnormal functioning along cortico–striato–thalamo–cortical (CSTC) 
  
pathways.2,10,16–18 Activity in this circuit was elevated in the basal state, accentuated 
during symptom provocation19–21 and nearly normal with successful treatment.22,23 
At a neurotransmission level, serotonin seems to have an important role in the 
pathophysiology of OCD, essentially due to the discovery of serotonin reuptake 
inhibitors (SRIs) efficacy in the treatment of OCD.24 In fact, brain imaging studies 
reported that certain regions in the brain have reductions in serotonin availability.25–27 
However, as mentioned above, only about half patients respond to treatment with 
SRIs28,  concluding that an explanation based only on serotonin deficit couldn´t 
completely illustrate the pathophysiology of this disease.  
In addition to the serotonin transporter system, there is growing evidence that 
disrupted neurotransmission of glutamate, the main neurotransmitter within the CSTC, 
is implicated in the pathogenesis of OCD.29,30 Research has shown significantly higher 
levels of glutamate in the cerebral spinal fluid and several sections of the brain, namely 
orbitofrontal cortex and caudate31–33, suggesting a role of glutamatergic hyperactivity 
and it´s consequent excitotoxicity and oxidative stress, in the pathophysiology of 
OCD.29,33–35 
Oxidative stress is attested by lipid peroxidation and alterations to antioxidant 
systems in serum samples of these patients.36–38 Symptom severity, as measured by 
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score, seems to be correlated with 
increased levels of oxidative stress.35,37,39 
As OCD is a phenotypically heterogeneous disorder with a broad range of 
symptomatic expression40, there has been increasing interest in identifying more 
uniform subtypes with distinct patterns of co-morbidities and outcomes.41  
American Psychiatric Association practice guidelines recommend cognitive-
behavioral therapy (CBT) that involves exposure and response prevention, and 
  
serotonin reuptake inhibitors (SRIs) as safe and effective first-line treatments for OCD. 
Despite the adequate treatment trials, 40% to 60% of patients preserve residual or 
impairing symptoms 42 and SRIs are not free from adverse side effects. The severity and 
nature of adverse reactions associated with the use of SRIs, particularly in the required 
higher doses, can often lead to treatment discontinuation. SRIs can lead to adverse 
effects such as anxiety, insomnia, nausea, diarrhea, headache, constipation, dizziness, 
sedation, decreased libido and sexual dysfunction.43–45 In addition to this, current 
antidepressant treatments need an extended waiting period, usually several weeks or 
even months, until the onset of symptom improvement.46  
Consequently, the investigation for more targeted pharmacologic agents and new 
augmentation strategies are crucial. 
Regarding this matter, in 2006, Lafleur and colleagues47  found promising results 
with the use of N-acetylcysteine (NAC). In addition to these results, the excellent 
tolerability profile and low-cost of NAC, raised a large expectation around this 
pharmacological agent. It cannot be obtained through diet, therefore, supplements are 
the only source.  
NAC is an acetylated precursor of the amino acid cysteine and has been widely 
used for its recognized ability as an antioxidant, by its metabolic contribution to 
glutathione (GSH) synthesis, in the treatment of acetaminophen overdose and as a 
mucolytic.48  
With oral administration, NAC is almost entirely converted to cysteine in the 
liver, which is mostly turned into GSH. Nevertheless, the remaining cysteine enters the 
systemic circulation and crosses the blood-brain barrier.48 Reaching the brain, cysteine 
is oxidized to cystine. Extracellular cystine is exchanged by intracellular glutamate by 
the cystine–glutamate antiporter (or x(c)-system), located mainly on glial cells in the 
  
brain49, thereby regulating extracellular glutamate levels and promoting cystine entry to 
the cell.50 Inside the cell, cystine can be reduced to cysteine, which is the limiting 
reagent for GSH assembly.53 
NAC might exert its therapeutic effect on OCD through two main mechanisms. 
First, NAC participates in the general antioxidant activities by its metabolic 
contribution to GSH production by providing an additional concentration of 
cysteine.53,54 Increased availability of GSH, scavenges toxic by-products of 
glutamatergic and dopamine metabolism, reducing oxidative and nitrosative stress, and 
thus cell damage.55 (Figure 1) 
 
 
 
 
 
 
 
 
 
Figure 1: 
Mechanism of action of NAC. When inside the brain, cysteine is oxidized to cystine. Extracellular cystine 
is exchanged by intracellular glutamate (Glu) by the cystine–glutamate antiporter (or x(c)-system), 
thereby regulating extracellular glutamate levels and promoting cystine entry to the cell. Inside the cell, 
cystine can be reduced to cysteine, which is the limiting reagent for GSH assembly. Non-vesicular 
glutamate in extracellular space, activates group II metabotropic glutamate receptors (mGluR2/3). These 
receptors negatively modulate the glutamatergic neurotransmission and excitotoxicity.  
 
Second, NAC modulates glutamatergic neurotransmission. The release of non-
vesicular glutamate to extracellular space caused by NAC, activates group II 
metabotropic glutamate receptors (mGluR2/3). These receptors are predominantly 
  
presynaptic and negatively modulate the glutamatergic neurotransmission and 
excitotoxicity.36,60 (Figure 1) 
The present work aimed to provide a systematic review of the current evidence 
available concerning the efficacy of NAC in the treatment of OCD.  
 
2. Methods 
A systematic review focusing on the efficacy of NAC on OCD was performed in 
accordance with PRISMA criteria.58  
 
2.1. Search Strategy 
An online literature search for publications regarding NAC in the treatment of 
OCD was conducted, until September 2017, in PUBMED, COCHRANE and SCIENCE 
DIRECT databases. The search algorithm included search terms - “N-
acetylcysteine“,“acetylcysteine” or “NAC” AND “obsessive compulsive disorder”. 
 
2.2. Eligibility Criteria 
The inclusion criteria were: (1) clinical trials and case reports studying the use of 
NAC in the treatment of OCD in adult and pediatric populations, (2) studies 
investigating the therapeutic effect of NAC as either a stand-alone or adjunctive 
treatment, (3) articles written in English. 
We excluded studies that (1) investigated an OCD-related disorder, as described 
by DSM-5, (2) did not involve humans, (3) were systematic reviews. 
 
2.3. Study Selection and Data Collection Process 
Studies were screened and selected by two reviewers. First, all titles and abstracts 
were read, and the inclusion and exclusion criteria were applied. Second, the articles 
  
considered for inclusion after selection by title/abstract reading were read fully, and the 
inclusion and exclusion criteria were applied again. The data collected from each study 
were: type of study, number of patients enrolled and mean age, co-morbidities of 
participants and concomitant medication, dose and duration of NAC treatment, outcome 
measures with respective baseline and endpoint scores.  
 
 
 
2.4. Level of evidence ratings 
 We provide a grade of recommendation (GOR) for the use of NAC in OCD based 
on the level of evidence (LOE) for each study. Using a well-established scale59, each 
Table 1 
Levels of evidence 
 
 
Level Description 
1a SR or meta-analysis of RCTs with homogeneity or Cochrane review with favorable findings 
1b 
 
Prospective high-quality RCT (medium sized with N between 50 and 100 or large sized with N over 
100 and/or higher validity trials based on adequate follow-up, intent to treat analysis, baseline 
similarity, equal treatment and dropout rates) 
2a SR of cohort (prospective, nonrandomized) studies with homogeneity 
2b Individual cohort (prospective, nonrandomized) study or low-quality RCT (small sized with N less 
than 50 and/or lower validity trials based on adequate follow-up, intent to treat analysis, baseline 
similarity, equal treatment and dropout rates) 
3a SR of case–control (retrospective) studies with homogeneity 
3b Individual case–control (retrospective) study 
4 Open label trials, case series or reports 
5 Expert opinion without critical appraisal or based on physiology or bench research 
    RCT: Randomized controlled trial; SR: Systematic review 
Table 2  
Grade of recommendation 
 
 
 
 
Grade Description 
A At least one level 1a study or two level 1b studies 
B At least one level 1b, 2a, or 3a study, or two level 2b or 3b studies 
C At least one level 2b or 3b study, or two level 4 studies 
D Level 5 evidence, or troublingly inconsistent or inconclusive studies of any level, or studies 
reporting no improvements 
N No studies identified 
  
study was individually assessed to determine the LOE, ranging from level 1 to 5 (Table 
1). After assessing all identified studies, a GOR ranging from A (solid evidence) to D 
(limited, inconsistent or inconclusive evidence) was assigned (Table 2).  
                
3. Results 
3.1. Search and Study Selection 
A total of 250 articles were identified by our query. Of these, 240 were excluded 
because they were review articles, were not performed in humans or included patients 
with OCD related disorders. Therefore, nine articles and one poster were included in our 
systematic review.  Five of the included articles are double-blind, placebo-controlled 
trials, and the other 5 are case reports. 
  
3.2. Evidence of effectiveness of NAC  
3.2.1. Case reports and case series (Table 3) 
In 2005, Lafleur et al.60 (N = 1; LOE 4), was the first to report the benefits of 
NAC in OCD. A significant improvement in OCD symptoms was described in a 58-
year-old woman with treatment-resistant OCD, by adding NAC to fluvoxamine therapy. 
Previously, this patient had not improved with other drugs and only had a partial 
response with 300mg/day of fluvoxamine, therapy that she had been taking for the 
preceding 12 years. During the 13-week trial, the SSRI drug was maintained throughout 
the NAC treatment period. The dose used in this study was initiated at 600 mg per os 
(P.O.) daily and titrated upward to a total daily dosage of 3000mg over seven weeks and 
maintained at this dose for the remaining six weeks. During the trial, there was an 
improvement on Yale-Brown Obsessive Compulsive Scale score (Y-BOCS). In the first 
week, was noticed a serious reduction in symptom severity, a drop of 8 points on the Y-
BOCS scale (from a baseline score of 32 to 24). At the end of the study, the Y-BOCS 
  
score was reduced to 9, with an overall reduction of 22 points from the beginning of this 
therapeutic intervention. The patient continued treatment with the same dose of 
fluvoxamine and NAC, and after a 2-month follow-up visit improvements were 
consistent.  
Posteriorly, in 2013, Van Ameringen et al.61 (N = 6; LOE 4) failed to demonstrate 
the efficacy of NAC add-on therapy in adult patients with treatment-resistant OCD. In 5 
of the six patients included in this study, no significant improvement of OCD symptoms 
was reported. The NAC treatment was started at 500 mg daily and was titrated up, 
depending on the clinical response and tolerability, to a mean dosage at the endpoint of 
2800 mg/day. One patient was lost to follow-up after six weeks, and the other five 
completed 12 weeks of treatment. These five had been taking 3000 mg/day of NAC for 
4 weeks at the study endpoint. The overall mean change from baseline score, as 
measured in Y-BOCS, was -1.3, with only one patient responding to NAC treatment 
(defined as a Clinical Global Impression-Severity (CGI-I) score of 2 and a 35% 
reduction in Y-BOCS, at the endpoint), with an overall reduction of  9 (Y-BOCS of 26 
at baseline, 17 at endpoint). 
Yazici et al.62 (N = 1; LOE 4), in 2014, reported the recovery achieved by adding 
NAC to citalopram in a 15-year-old female with treatment-resistant OCD.  The patient 
was supplemented with NAC, which was titrated from 600 mg to 2400 mg daily over 
six weeks and maintained for further 18 weeks, while treatment with 60 mg/day 
citalopram was continued. In 24 weeks, a significant drop in symptom severity was 
detected as measured by the Y-BOCS, with a baseline score of 37 reduced to 9. This is 
considered a “full response”, according to Pallanti and Quercioli42 response 
classification (decrease in YBOCS score greater than 35% and a CGI-S of 1 or 2). 
  
More recently, in 2015, these authors have published a series of 5 case reports 63 
(N = 5; LOE 4), also in pediatric age. All patients were initially treated with NAC 600 
mg daily, as augmentation therapy. The NAC dosage was then titrated up, taking into 
consideration the clinical response and side effects, to a final dosage that varied from 
1800 mg to 3000mg. Four of the 5 participants showed significant improvement with 
NAC augmentation therapy, after 24 weeks follow-up. Two experienced “full 
response”, as defined above; the other two patients entered “remission”, considered 
when Y-BOCS score is less than 16. The remaining patient, considered as a “non-
responder”, had a decrease in Y-BOCS score less than 25% and CGI-S of 4. The overall 
mean change in Y-BOCS from baseline was - 17. 
Saraiva et al. (2015)64 (N = 1; LOE 4) described a complete remission of all 
symptoms in a 44-year-old man with resistant OCD, after NAC (1200mg/day) 
augmentation to paroxetine and risperidone. No adverse side effects were reported. 
 
3.2.2. Clinical Trials (Table 4) 
To assess the efficacy and safety of NAC, as an augmentation treatment in 
patients with treatment-refractory OCD, Afshar et al.65 (N =48; LOE 2b) performed a 
12-week randomized, double-blind, placebo-controlled clinical trial. In this study, 48 
adult patients, with  mean age of 31 years, were randomized into two equal groups and 
treated with SRIs, at the same dose as in the pre-intervention, plus either placebo or 
NAC. The intervention group was supplemented with 2400mg NAC daily, which was 
titrated from 600 mg and doubled weekly considering the clinical improvement and 
tolerance. The effects of NAC in the reduction of Y-BOCS score were significant over 
time and in comparison with the placebo group. Likewise, significant improvement in 
symptom severity, as measured by mean Y-BOCS reduction, was noticed by the end of 
the eighth week to the end of the study. At study endpoint, the mean reduction in Y-
  
BOCS score was 11 in the NAC group and 6 in control group. Fifty-three percent of 
NAC-treated patients evidenced a clinical response at the end of the study, defined as a 
≥35% reduction in Y-BOCS score, which was significantly higher than the control 
group (15%). Regarding side effects, NAC-treated participants experienced significantly 
higher rates of gastrointestinal adverse events. 
In 2015, Sarris et al.66 (N =44; LOE 2b) published the results of another 
randomized, double-blind, placebo-controlled clinical trial using a higher dose of NAC, 
3000 mg/day (1500mg twice daily), in OCD patients (with ≥16 points in Y-BOCS 
score, at baseline). In this 16-week study, NAC was titrated from 1000 mg/day and 
elevated 1000 mg weekly. The mean age of the 44 study participants was 37 years with 
the majority (70.5%) taking psychotropic drugs, over half (56.8%) having SSRI and 
about one third (29,5%) were utilizing adjunctive therapies. In term of results, an 
apparent effect was emerging by week 12, however, at the endpoint, this study failed to 
show a significant time x treatment interaction for Y-BOCS total score. Despite this, a 
significant time x treatment interaction was described for the Y-BOCS compulsions 
subscale in NAC group, with a significant reduction detected at the twelfth week, 
although dissipated at the sixteenth. Overall, at week 16, 20% of NAC-treated patients 
evidenced a clinical response, defined as a ≥35% reduction in Y-BOCS score, compared 
with 27% in placebo group. NAC was well-tolerated with no differences in the total 
adverse events between the groups. Nevertheless, heartburn was the only clinical 
adverse event experienced in significantly higher rates in NAC group. 
One year later, the same authors 67 explored this data further and released an 
analysis of potentially modifying factors, such as age, severity and duration of illness, 
OCD presentation type, baseline anxiety and depression score and the use of 
  
antidepressant medications. They concluded that NAC is more effective in younger 
people with a shorter duration of OCD diagnosis.  
Paydary et al. (2016)68 (N =44; LOE 2b) performed a ten-week randomized, 
double-blind, placebo-controlled clinical trial to evaluate the efficacy of NAC as an 
augmentation therapy compared to fluvoxamine monotherapy. In this work, 44 adult 
patients, with moderate to severe OCD (≥21 in Y-BOCS score), were randomized into 
two identical groups and treated with a SSRI (200mg/day of fluvoxamine), plus either 
placebo or NAC. All patients took fluvoxamine 100mg/day in the first four weeks and 
200mg/day for the rest of the study. The NAC group was supplemented with 2000mg 
NAC daily (1000mg bid), which was titrated from 1000 mg (500 twice daily) and 
doubled in the first week. Results analysis revealed a significant time x treatment 
interaction for the Y-BOCS total score and the Y-BOCS obsession subscale score. The 
difference between mean scores of Y-BOCS total score, Y-BOCS obsession subscale 
score, and Y-BOCS compulsion subscale score was not significant between the two 
groups at each time point of the trial. Furthermore, 12 NAC-treated participants 
accomplished remission (Y-BOCS score at the endpoint ≤16), compared to 5 patients in 
the control group, which was almost significant (p=0.062). Regarding side effects, 
NAC-treated participants did not experience significantly higher rates of adverse events. 
Ghanizadeh and colleagues (2017)69 (N =34; LOE 2b) conducted a randomized, 
double-blind, placebo-controlled trial to evaluate the possible effects of NAC as an 
augmentation therapy compared to citalopram monotherapy in the treatment of children 
and adolescents (10 to 21 years) with OCD. In this 10-week trial, 34 patients were 
randomized into two groups to receive citalopram (20 to 40 mg/day) plus placebo or 
citalopram (20 to 40 mg/day) plus NAC (titrated up to 2400mg/day over six weeks). 
Results showed a significant decrease in the Y-BOCS score in the NAC-treated group 
  
from the fourth week to the end of the trial. In fact, the Y-BOCS score decreased from 
21 to 11 in the NAC group during this study. Also, the Y-BOCS score at the end of the 
trial was significantly different between the two groups. The mean difference of Y-
BOCS score was not statistically different between the two groups, at each time point of 
the trial. The mean score of change for “resistance/control to compulsion”- the sum of 
items 9 and 10 scores of Y-BOCS - in NAC group was significantly higher compared to 
placebo. Regarding side effects, there was no statistical difference between groups.  
The most recent randomized, double-blind, placebo-controlled trial evaluating the 
effectiveness of NAC as an SRI augmentation treatment was conducted by Costa et al. 
(2017)70 (N =40; LOE 2b). In this trial, an adult treatment-resistant cohort of 40 
patients, with a mean age of 38 years, was randomized to NAC (dose titrated from 
1200mg/day to a maximum of 3000 mg/day over two weeks) and placebo. All 
participants were concomitantly taking at least an SRI, by international OCD treatment 
guidelines.71,72 The obtained results demonstrated a non-significant difference in Y-
BOCS scores between groups at the end of the study. A significant reduction in Y-
BOCS score was noticed in NAC treated group over time. However, the control group 
showed an identical improvement. In a secondary analysis, patients treated with NAC 
had a significant reduction in anxiety, as measured by Beck Anxiety Inventory (BAI) 
score, compared to placebo group. The frequency of adverse events did not differ 
significantly between groups, except for “stomach/abdominal pain”. 
 
 
  
Table 3  
Case reports and case series 
 
Study  Study design  N Mean 
Age 
Co-morbidities Dosage  Duration Concomitant 
medication 
Outcome 
measure 
Baseline 
score  
End 
point 
score 
Results  Evidence 
of efficacy 
Lafleur et al.  
2005 60 
Case report 1 58  Recurrent MDD (in 
remission at the time 
of the trial) 
3000mg daily, 
titrated from 600 
mg over 6 weeks 
13 weeks Fluvoxamine (300mg/d) Y-BOCS 
 
32 9 Marked 
improvement in 
Y-BOCS 
4 
Yazici et al. 
2014 62 
Case report 1 15  2400mg daily, 
titrated from 
600mg  over 6 
weeks 
24 weeks Citalopram (60mg/d) Y-BOCS 37 9 Marked 
improvement in 
Y-BOCS 
4 
Yazici et al. 
2015 63 
Case Series 5 11 MDDb,d; 
Epilepsyd 
1800-3000mg 
daily, titrated 
from 600mg   
24 weeks Citalopram (60mg/d) 
and Aripiprazole 
(20mg/d)a1 
Clomipramine 
(150mg/d) and 
Aripiprazole (30mg/d)b1 
Clomipramine 
(150mg/d)c1 
Citalopram (60mg/d)d1 
Fluoxetine (30mg/d)e1 
Y-BOCS, 
CGI-S 
39a 
39b 
37c 
39d 
34e 
13a 
35b 
23c 
23d 
9e 
Marked 
improvement in 
Y-BOCS in 4 of 
the 5 patients  
4 
Saraiva et al.  
2015 64 
Case Report 1 44 NR 1200mg/d NR Paroxetine (60mg/d) 
and Risperidone 
(2mg/d) 
NR NR NR Complete 
remission of all 
symptoms 
4 
Van 
Ameringen et 
al. 
2012 61 
Case Series 6 54 Tourette’s syndrome 
a2; MDD a2; b2; f2; 
dysthymia a2; f2 ; skin 
picking f2 
; trichotillomania f2 ; 
ADHD f2 ; MDEc2 ; 
panic disorder with 
agoraphobiad2; social 
phobia d2 ; generalised 
anxiety disorder d2 ; 
substance abuse d2 
Mean of 2800 
mg/d, titrated 
from 500mg  (5 
patients had been 
taking 3000mg/d 
for 4 weeks at 
study endpoint) 
12 weeks All patients were taking 
2 or more psychotropic 
agents  
Y-BOCS, 
CGI-S 
31 a2 
29 b2 
26 c2 
34 d2 
31 e2 
25 f2 
32 a2 
36 b2 
17 c2 
30 d2 
28 e2 
25 f2 
Only 1 met 
response criteria  
4 
 
Abbreviations: a1: case 1 from Yazici et al. 2015; b1: case 2 from Yazici et al. 2015; c1: case 3 from Yazici et al. 2015; d1: case 4 from Yazici et al. 2015; e1: case 5 from Yazici et al. 2015; NR: not reported; a2: case 1 from Van Ameringen et al. 
2012; b2: case 2 from Van Ameringen et al. 2012; c2: case 3 from Van Ameringen et al. 2012; d2: case 4 from Van Ameringen et al. 2012; e2: case 5 from Van Ameringen et al. 2012; f2: case 1 from Van Ameringen et al. 2012; ADHD: Attention 
deficit hyperactivity disorder; MDD: major depressive disorder; MDE: major depressive episode; NAC: N-acetylcysteine; CGI-S: Clinical Global Impressions severity 
  
Table 4 
Clinical Trials 
Study  Study design  N 
 
Age 
 -Mean 
 -Range 
Co-morbidities Dosage  Duration 
-With 
titration 
-Without 
titration 
 
Concomitant 
medication 
Outcome 
measure 
Mean 
Baseline 
score  
Mean
End 
point 
score 
Results  Evidence 
of 
efficacy 
Afshar et al. 
2012 65 
RDBPCT 48(39) 31 
18-45 
NR 2400mg daily, 
titrated from 
600mg  
12 weeks 
 9 weeks 
 
SRI ONLY* Y-BOCS, 
CGI-S and 
CGI-I 
28 17 Significant 
improvement in 
Y-BOCS 
2b 
Sarris et al. 
2015 66 
RDBPCT 44(34) 37 
18-70 
56.8% had a 
DSM-IV 
diagnosed 
comorbid 
psychiatric 
disorder 
3000mg daily 
titrated from 
1000mg 
16 weeks 
13 weeks 
70.5 % psychotropic 
drugs; 56.8% SSRI; 
29.5 % adjunctive 
therapies such as 
antipsychotics. # 
Y-BOCS, 
CGI-S; CGI-I; 
HAM–A; 
MADRS; 
GHQ-28 
27 22 No significant 
improvement in 
Y-BOCS;   
Significant 
reduction in Y-
BOCS 
compulsions 
subscale score at 
week 12 
2b 
Paydary et al. 
2016 68 
RDBPCT 44(44) 33 
18-60 
Comorbid DSM-
IV axis I 
disorders were 
exclusion 
criteria 
2000mg daily 
titrated from 
1000mg 
10 weeks 
 9 weeks 
Fluvoxamine ONLY 
(200mg/day) + 
 
Y-BOCS 27 NR Significant 
improvement in 
Y-BOCS total 
score and in Y-
BOCS obsession 
subscale score 
2b 
Ghanizadeh et 
al. 
2017 69 
RDBPCT 34(29) 16 
10-21 
NR 2400mg daily 
titrated from 
600mg 
10 weeks 
 4 weeks 
Citalopram ONLY (20 to 
40 mg/day) + 
 
Y-BOCS; 
PedsQL™ 4.0 
21 11 Significant 
improvement in 
Y-BOCS score  
2b 
Costa et al. 
2017 70 
RDBPCT 40(35) 38 
18-65 
OCD only 
22.5% 
3000mg daily 
titrated from 
1200mg 
16 weeks 
14 weeks 
At least an SRI* 
 
SRI ONLY 25% 
SRI+ antipsychotic 
37.5% 
SSRI+clomipramine12.5
% 
SRI+other &25% 
Y-BOCS; 
BAI; BDI; 
BABS; DY-
BOCS 
26 21 No Significant 
improvement in 
Y-BOCS score 
but significant 
reduction in BAI 
score 
2b 
 
Abbreviations: RDBPCT: randomized, double-blind, placebo-controlled trial; SRI: Serotonin Reuptake Inhibitor; SRI: Serotonin reuptake inhibitor; *: The SRI drug is not specified; #: stable treatment regimen for a minimum of 4weeks of current 
treatment and a minimum of 12 weeks if it was their first OCD treatment; HAM–A: Hamilton Anxiety Rating Scale; MADRS: Montgomery– Asberg Depression Rating Scale; GHQ-28: General Health Questionnaire; (CGI–S, CGI–I): Clinical 
Global Impression Scales–Severity and –Improvement; PedsQL™ 4.0: Pediatric Quality of life Inventory; +: initiated with the study; BAI: Beck Anxiety Inventory; BDI: Beck Depression Inventory; BABS: Brown Assessment of Beliefs Scale; 
DY-BOCS: Dimensional Y-BOCS; &: mood stabilizers, sedatives, hypnotics, other antidepressants, and stimulants 
  
4. Discussion 
In a field where current treatments are limited, have suboptimal efficiency and an 
extensive spectrum of side effects, the search for alternatives is essential. Some authors 
suggest that NAC, due to its antioxidant effects and glutamatergic neurotransmission 
modulation, may be a promising pharmacological treatment for OCD. We 
systematically reviewed all published studies (in English) up to date assessing the 
efficacy of NAC in OCD, including clinical trials, case series and case reports. 
Since the first case report in 2006 60, five clinical trials, 2 case reports, and 2 case 
series have been published. All case reports and case series demonstrated a marked 
improvement in symptoms with NAC augmentation therapy, except that carried out by 
Van Ameringen et al.61 This failure could be attributable to some factors. First, the 
shortest duration of NAC intake at the maximum dose (4 weeks), compared to Lafleur 
et al.60 (7 weeks), Yazici et al.62 (18 weeks) and Yazici et al.63 (at least 22 weeks). 
Second, half of the participants (3 out of 6) also had at least one comorbid diagnosis, 
other than depression. To corroborate this hypothesis, the responder patient had a 
history of only one comorbid disorder, which was a previous episode of major 
depressive disorder. Depression is highly prevalent during the natural course of OCD. 
Third, although all patients reported full compliance with treatment, one cannot be 
entirely sure that this is true, as they had to purchase and consume the correct dose of 
NAC on their own. The authors have not objectively verified the adherence to an 
adequate treatment regimen. In the other studies, similar problems could have also 
occurred. However, compliance may have been more accurate since the patient in the 
Lafleur et al. case report 60 was at the inpatient unit throughout the treatment and the 
other two studies were conducted on children under parental care. 
  
On the other hand, several factors may have contributed to an overestimation of 
the effect of NAC in the studies mentioned above. For example, the patient of Lafleur et 
al.60 was hospitalized during the treatment period, receiving supportive psychotherapy, 
which was not a formal or manual driven cognitive-behavioral treatment plan but may 
have positively influenced the results. It is also important to note that in “case 1” of 
Yazici et al.63, the introduction of NAC was made only after four weeks of the increase 
of citalopram and this drug could have elicited its full response during the study.  
In Saraiva et al.64 no obsessive symptom rating scale was used. The 
"classification" of the symptomatic improvement was based on the patient's interview 
and report. 
The five clinical trials included in this review showed non-consensual results; 3 of 
them proclaimed NAC as a promising therapy in OCD patients. After the full analysis 
of their methodologies, we could delineate some aspects that can justify their 
differences.  
In Afshar et al.65, Paydary et al.68 and Ghanizadeh et al.69 the concomitant 
medication used during NAC supplementation was composed of only one drug, in 
particular, an SRI. The other two studies used different concomitant psychotropic drugs 
between participants and in Sarris et al.66 NAC was used in monotherapy in 29.5% of 
patients.  
Apparently, the existence of comorbidities may mitigate the therapeutic effects of 
NAC in OCD. In Sarris et al.66 almost 60% of patients had a comorbid psychiatric 
disorder, and in Costa et al.70 only 22.5% suffered only from OCD. It would be 
important to know the specific psychiatric comorbidities. Nevertheless, some clinical 
trials did not record any information about comorbidities in their participants. The 
clinical trials in which patients have the higher mean age are the same that have not 
  
achieved significant positive outcomes. However, we have to keep in mind that older 
patients may also be the ones with longer disease duration. Hence, this factor, and not 
the age itself, can be the real modifying factor for NAC efficacy. This possibility was 
suggested in a post hoc analysis of the clinical trial conducted by Sarris et al.67  
In the clinical trial of Sarris et al.66 a 75% tablet consumption rate was considered 
to be the minimum threshold for compliance. Therefore, the low response rate reported 
could be attributable to the suboptimal patient compliance. These differences could also 
be explained by the fact that to achieve maximum NAC effect it would require a 
treatment duration over than 16 weeks. Considering the titration phase, these study 
periods did not reflect the duration of full NAC dose.  
We may not forget that OCD has a heterogeneous neurobiology nature. Therefore, 
the efficacy of NAC could be limited to a subset of people with polymorphisms in 
glutamate genes. Additionally, the necessary NAC dose to perform its neurobiological 
functions could be different for a subset of patients. 
Ghanizadeh et al.69 and Sarris et al.66 demonstrated a higher reduction in 
compulsions compared to obsessions. However, Paydary et al.68 showed the opposite 
results. For this reason, efforts must be made to explore whether NAC may exert a 
preferential effect on compulsions or obsessions. 
Future clinical trials need to address some important methodological issues to 
provide more definitive answers regarding the benefits of NAC for OCD. For example, 
there is a crucial need for larger samples to detect moderate or small effect sizes. 
Additionally, trials may also need longer follow-up times, as it is not clear the NAC 
latency time for efficacy and if this effect can be maintained over time. It would be 
important to sustain the follow-up for some time after discontinuation of NAC, in order 
  
to detect symptom relapsing. Dose-finding studies are still a need, as it remains to be 
demonstrated if higher doses correlate with greater efficacy.  
Future research with magnetic resonance imaging (MRI) or functional MRI brain 
imaging would also be important, in order to understand in more detail what are the 
specific effects of NAC in brain activity that contribute to reduce symptoms in some 
patients and, consequently, expand the knowledge of the pathophysiology of this 
disease. 
The beneficial effects of NAC could also be limited by its low bioavailability. 
Therefore esterification of the carboxyl group of NAC to produce N-acetylcysteine 
ethyl ester (NACET) would enhance its lipophilicity and, consequently, its 
pharmacokinetics73. In this way, NACET could be employed in future clinical trials as it 
holds the potential to be more effective than NAC. 
As we expected, NAC used in doses ranging from 1200 mg to 3000 mg, has 
proved an optimal tolerability profile and the most frequently reported adverse events 
were gastrointestinal. This information is in accordance with previous research using 
NAC for other diseases. In fact, De Rosa et al.74 showed that doses up to 8000 mg/day 
are not known to cause any clinically significant adverse reaction.  
Regarding the level of evidence of the studies included in this systematic review, 
and the fact that some of these studies have not proven the efficacy of NAC in the 
treatment of OCD, we consider that the GOR for using this pharmacological agent in 
the treatment of OCD is D.  
 
 
 
 
  
5. Conclusion 
We would expect NAC to have a beneficial effect on OCD symptoms due to what 
is known about the pathophysiology of OCD. However, up to now, there are 
contradictory results.  
It must be taken into consideration that the two RCTs that have not showed 
positive results tend to be the ones with more confounding variables, such as the use of 
different concomitant psychotropic drugs or the existence of other psychiatric 
comorbidities. 
In this way, despite the degree of evidence being D, our opinion is that the 
potential value of NAC is being underestimated. Considering the level of disability 
caused by resistant OCD, and the exceptional tolerability profile of NAC, its use as an 
add-on agent should be contemplated, on an ad hoc basis. Furthermore, the only 
relevant side effect associated with NAC, diarrhoea, may also have clinical utility, as it 
can counterbalance constipation caused by other psychopharmaceuticals commonly 
used in OCD treatment.   
It is essential to consider further studies to better elucidate the potential role of 
NAC in the treatment of OCD. These studies should preferentially be RCTs with larger 
number of participants and proper time of follow up. Additionally, it would also be 
important to have a better characterization of the participants included in the study, 
namely the mean age, mean duration of disease and symptom dimensions. Other aspects 
that can interfere with the efficacy of NAC in the treatment of OCD are the presence of 
other psychiatric diseases, concomitant treatments (pharmacological and non 
pharmacological) and adherence to prescribed therapies. These variables should also be 
evaluated in future studies. 
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GUIDE FOR AUTHORS
.
Your Paper Your Way
We now differentiate between the requirements for new and revised submissions. You may choose to
submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when
your paper is at the revision stage, will you be requested to put your paper in to a 'correct format'
for acceptance and provide the items required for the publication of your article.
To find out more, please visit the Preparation section below.
INTRODUCTION
Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and
multidisciplinary research, review and news journal. One of its main aims is to assure rapid publication
of authoritative reviews and research papers dealing with experimental and clinical aspects of
neuro-psychopharmacology and biological psychiatry. Another important aim of the journal is to
supply pertinent information, provided by national and international bodies, that contributes to
progress in the scientific and professional fields. Finally, the journal intends to foster and encourage
communications between members of the communities of neuro-psychopharmacology and biological
psychiatry.
Studies on natural products The journal does not publish work on the actions of biological extracts
unless the pharmacological active molecular substrate and/or specific receptor binding properties of
the extract compounds are elucidated.
Types of paper
1. Original research articles
2. Review articles: Mini-reviews or comprehensive reviews of cutting edge work, or syntheses of
cutting edge work that has been done in the past two years.
Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for
review. Please check the relevant section in this Guide for Authors for more details.
Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
All necessary files have been uploaded:
Manuscript:
• Include keywords
• All figures (include relevant captions)
• All tables (including titles, description, footnotes)
• Ensure all figure and table citations in the text match the files provided
• Indicate clearly if color should be used for any figures in print
Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)
Further considerations
• Manuscript has been 'spell checked' and 'grammar checked'
• All references mentioned in the Reference List are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the
Internet)
• A competing interests statement is provided, even if the authors have no competing interests to
declare
• Journal policies detailed in this guide have been reviewed
• Referee suggestions and contact details provided, based on journal requirements
For further information, visit our Support Center.
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BEFORE YOU BEGIN
Ethics in publishing
Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.
Human and animal rights
If the work involves the use of human subjects, the author should ensure that the work described has
been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration
of Helsinki) for experiments involving humans; Uniform Requirements for manuscripts submitted to
Biomedical journals. Authors should include a statement in the manuscript that informed consent
was obtained for experimentation with human subjects. The privacy rights of human subjects must
always be observed.
All animal experiments should comply with the ARRIVE guidelines and should be carried out in
accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU
Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care
and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should
clearly indicate in the manuscript that such guidelines have been followed.
Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations
that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include
employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/
registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A
summary declaration of interest statement in the title page file (if double-blind) or the manuscript file
(if single-blind). If there are no interests to declare then please state this: 'Declarations of interest:
none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed
disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official
records. It is important for potential interests to be declared in both places and that the information
matches. More information.
Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in
the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent
publication' for more information), that it is not under consideration for publication elsewhere, that
its publication is approved by all authors and tacitly or explicitly by the responsible authorities where
the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in
English or in any other language, including electronically without the written consent of the copyright-
holder. To verify originality, your article may be checked by the originality detection service Crossref
Similarity Check.
Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy.
Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple,
redundant or concurrent publication' for more information).
Contributors
Each author is required to declare his or her individual contribution to the article: all authors must have
materially participated in the research and/or article preparation, so roles for all authors should be
described. The statement that all authors have approved the final article should be true and included
in the disclosure.
Addition, deletion, or rearrangement of author names in the authorship of accepted
manuscripts
Before the accepted manuscript is published in an online issue
Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal
Manager from the corresponding author of the accepted manuscript and must include:
The reason the name should be added or removed or the author names rearranged. Written
confirmation (email, fax, letter) from all authors that they agree with the addition, removal or
rearrangement. In the case of addition or removal of authors, this includes confirmation from the
author being added or removed.
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Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to
the corresponding author, who must follow the procedure as described above. Note that:
Journal Managers will inform the Journal Editors of any such requests. Publication of the accepted
manuscript in an online issue is suspended until authorship has been agreed.
After the accepted manuscript is published in an online issue Any requests to add, delete, or rearrange
author names in an article published in an online issue will follow the same policies as noted above
and result in a corrigendum.
Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their
manuscript and provide the definitive list of authors at the time of the original submission. Any
addition, deletion or rearrangement of author names in the authorship list should be made only
before the manuscript has been accepted and only if approved by the journal Editor. To request such
a change, the Editor must receive the following from the corresponding author: (a) the reason
for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they
agree with the addition, removal or rearrangement. In the case of addition or removal of authors,
this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of
authors after the manuscript has been accepted. While the Editor considers the request, publication
of the manuscript will be suspended. If the manuscript has already been published in an online issue,
any requests approved by the Editor will result in a corrigendum.
Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see
more information on this). An e-mail will be sent to the corresponding author confirming receipt of
the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version
of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal
circulation within their institutions. Permission of the Publisher is required for resale or distribution
outside the institution and for all other derivative works, including compilations and translations. If
excerpts from other copyrighted works are included, the author(s) must obtain written permission
from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for
use by authors in these cases.
For open access articles: Upon acceptance of an article, authors will be asked to complete an
'Exclusive License Agreement' (more information). Permitted third party reuse of open access articles
is determined by the author's choice of user license.
Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More
information.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.
Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or
preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in
the collection, analysis and interpretation of data; in the writing of the report; and in the decision to
submit the article for publication. If the funding source(s) had no such involvement then this should
be stated.
Funding body agreements and policies
Elsevier has established a number of agreements with funding bodies which allow authors to comply
with their funder's open access policies. Some funding bodies will reimburse the author for the Open
Access Publication Fee. Details of existing agreements are available online.
Open access
This journal offers authors a choice in publishing their research:
AUTHOR INFORMATION PACK 18 Mar 2018 www.elsevier.com/locate/pnp 6
Subscription
• Articles are made available to subscribers as well as developing countries and patient groups through
our universal access programs.
• No open access publication fee payable by authors.
Open access
• Articles are freely available to both subscribers and the wider public with permitted reuse.
• An open access publication fee is payable by authors or on their behalf, e.g. by their research funder
or institution.
Regardless of how you choose to publish your article, the journal will apply the same peer review
criteria and acceptance standards.
For open access articles, permitted third party (re)use is defined by the following Creative Commons
user licenses:
Creative Commons Attribution (CC BY)
Lets others distribute and copy the article, create extracts, abstracts, and other revised versions,
adaptations or derivative works of or from an article (such as a translation), include in a collective
work (such as an anthology), text or data mine the article, even for commercial purposes, as long
as they credit the author(s), do not represent the author as endorsing their adaptation of the article,
and do not modify the article in such a way as to damage the author's honor or reputation.
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective
work (such as an anthology), as long as they credit the author(s) and provided they do not alter or
modify the article.
The open access publication fee for this journal is USD 2200, excluding taxes. Learn more about
Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing.
Green open access
Authors can share their research in a variety of different ways and Elsevier has a number of
green open access options available. We recommend authors see our green open access page for
further information. Authors can also self-archive their manuscripts immediately and enable public
access from their institution's repository after an embargo period. This is the version that has been
accepted for publication and which typically includes author-incorporated changes suggested during
submission, peer review and in editor-author communications. Embargo period: For subscription
articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers
before an article becomes freely available to the public. This is the embargo period and it begins from
the date the article is formally published online in its final and fully citable form. Find out more.
This journal has an embargo period of 12 months.
Elsevier Researcher Academy
Researcher Academy is a free e-learning platform designed to support early and mid-career
researchers throughout their research journey. The "Learn" environment at Researcher Academy
offers several interactive modules, webinars, downloadable guides and resources to guide you through
the process of writing for research and going through peer review. Feel free to use these free resources
to improve your submission and navigate the publication process with ease.
Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of
these). Authors who feel their English language manuscript may require editing to eliminate possible
grammatical or spelling errors and to conform to correct scientific English may wish to use the English
Language Editing service available from Elsevier's WebShop.
Submission
Our online submission system guides you stepwise through the process of entering your article
details and uploading your files. The system converts your article files to a single PDF file used in
the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for
final publication. All correspondence, including notification of the Editor's decision and requests for
revision, is sent by e-mail.
Submit your article
Please submit your article via http://ees.elsevier.com/pnp/
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Referees
Please submit the names and institutional e-mail addresses of several potential referees. For more
details, visit our Support site. Note that the editor retains the sole right to decide whether or not the
suggested reviewers are used.
Genetic Association Studies
Progress in Neuro-Psychopharmacology & Biological Psychiatry is interested in Genetics/Association
studies that are replicable and generalizable. The following guidelines are offered in pursuit of this
goal. (1) Studies need to be sufficiently large. (2) Information about subject ethnicity, and how
it was determined, should be provided. The use of an analytic strategy that controls for potential
stratification, such as family-controlled association, or structured association, is encouraged. (3)
There must be a clear description of how the phenotype was ascertained. (4) Negative studies should
always include estimates of power.
Confirmation of the functional consequences of a common disease-associated variant is useful
information, but does not substitute for a rigorous demonstration of a statistically significant
association. Analysis of pathways or candidate regional analysis is encouraged over single gene
studies. Candidate gene studies must have strong positional or biological rationale or precedents in
the literature that motivate gene choice.
For studies of non-functional variants, there should generally be sufficiently dense marker coverage
to allow a relatively comprehensive analysis of common variants within a gene or genes. Analysis
of the extent of marker coverage using standard methods to assess linkage disequilibrium should
be presented. If rare variants are being tested, the same method of assessment (sequencing, copy
number assessment, etc.) should be used in both case and control groups.
We will consider both negative and positive association studies, as well as large replication studies.
Negative studies should be based on an attempt to replicate previous studies. Power calculations
considering reasonable effect sizes must be provided to show that the study had sufficient power to
be informative.
PREPARATION
NEW SUBMISSIONS
Submission to this journal proceeds totally online and you will be guided stepwise through the creation
and uploading of your files. The system automatically converts your files to a single PDF file, which
is used in the peer-review process.
As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file
to be used in the refereeing process. This can be a PDF file or a Word document, in any format or lay-
out that can be used by referees to evaluate your manuscript. It should contain high enough quality
figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at
the initial submission. Please note that individual figure files larger than 10 MB must be uploaded
separately.
References
There are no strict requirements on reference formatting at submission. References can be in any style
or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book
title, chapter title/article title, year of publication, volume number/book chapter and the pagination
must be present. Use of DOI is highly encouraged. The reference style used by the journal will be
applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted
at proof stage for the author to correct.
Formatting requirements
There are no strict formatting requirements but all manuscripts must contain the essential elements
needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and
Methods, Results, Conclusions, Artwork and Tables with Captions.
If your article includes any Videos and/or other Supplementary material, this should be included in
your initial submission for peer review purposes.
Divide the article into clearly defined sections.
Figures and tables embedded in text
Please ensure the figures and the tables included in the single file are placed next to the relevant text
in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should
be placed directly below the figure or table.
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Peer review
This journal operates a single blind review process. All contributions will be initially assessed by the
editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of
two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible
for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More
information on types of peer review.
REVISED SUBMISSIONS
Use of word processing software
Regardless of the file format of the original submission, at revision you must provide us with an
editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting
codes will be removed and replaced on processing the article. The electronic text should be prepared
in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with
Elsevier). See also the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check'
functions of your word processor.
LaTeX
You are recommended to use the Elsevier article class elsarticle.cls to prepare your manuscript and
BibTeX to generate your bibliography.
Our LaTeX site has detailed submission instructions, templates and other information.
Article structure
Title
The title of the paper should be brief; no longer than 100 characters in length, and should capture
and communicate the key message of your research to a broader audience. To aid this, abbreviations,
unless familiar to a broad audience, should be avoided.
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered
1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this
numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be
given a brief heading. Each heading should appear on its own separate line.
Original research articles should be organized as follows:
Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature
survey or a summary of the results.
Methods
This section should contain explicit, concise descriptions of all procedures, materials and methods
used in the investigation to enable the reader to judge their accuracy, reproducibility, etc. To increase
clarity, headings should be used throughout. For example, the following subheadings, which should
be numbered, could be used:
Experimental articles: Animals, Drugs, Apparatus, Experimental procedure, and Statistical analysis.
Clinical articles: Patient population, Drug administration, Study design, Assessment instruments, and
Data analysis. Depending on the type of article they are preparing, authors could introduce any other
subheadings they find useful.
Results and statistical analyses
This section usually contains the experimental data, but no extended discussion of their significance.
The main statistical results should be reported under this section. The description of the statistical
results should include the proper statistical term (such as the F statistic) as well as the degrees of
freedom and the P value. The description of statistical results in the figure legends should be limited
to important post hoc comparisons. The results should be illustrated (figures and tables); data are
usually easier for readers to grasp if they are represented in graphic or tabular form, rather than
discursively. Graphic presentation of data is preferred. Data should not be needlessly repeated in text.
Sufficient data may allow interested but non-expert readers to judge the variability and reliability of
the results. The section should be well structured using appropriate subheadings.
The main statistical results should be reported in the Results section. The description of the statistical
results should include the proper statistical term (such as the F statistic) as well as the degrees of
freedom and the P value. The description of statistical results in the figure legends should be limited
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to important post hoc comparisons. For example, you should report F value and degree of freedom
Anova F(x,y)= 5.67, p<0.05. For t-test t= -0.722, df =x, p =0.05. For Chi square Χ2=9.882, df=3
p=0.01, Χ2=9.882, df=3 p=0.017 etc).
Fisher's least significant differences (LSD) tests are not acceptable as they are too permissive. ANOVA
followed by an appropriate post-hoc test (ie Tukey-Kramer, etc) should be performed.
Discussion
This should be pertinent to the results. Speculative discussion is not discouraged provided it is based
on the data presented. The discussion should be as concise as possible and well structured, using
appropriate subheadings.
Conclusion
A short paragraph of conclusions (5 to 10 lines) should be included.
Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid
abbreviations and formulae where possible.
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s)
of each author and check that all names are accurately spelled. You can add your name between
parentheses in your own script behind the English transliteration. Present the authors' affiliation
addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-
case superscript letter immediately after the author's name and in front of the appropriate address.
Provide the full postal address of each affiliation, including the country name and, if available, the
e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing
and publication, also post-publication. This responsibility includes answering any future queries about
Methodology and Materials. Ensure that the e-mail address is given and that contact details
are kept up to date by the corresponding author.
• Present/permanent address. If an author has moved since the work described in the article was
done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as
a footnote to that author's name. The address at which the author actually did the work must be
retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
Abstract
A concise and factual abstract is required. The abstract should state briefly the purpose of the
research, the principal results and major conclusions. An abstract is often presented separately from
the article, so it must be able to stand alone. For this reason, References should be avoided, but if
essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should
be avoided, but if essential they must be defined at their first mention in the abstract itself.
Graphical abstract
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online
article. The graphical abstract should summarize the contents of the article in a concise, pictorial form
designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a
separate file in the online submission system. Image size: Please provide an image with a minimum
of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 ×
13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office
files. You can view Example Graphical Abstracts on our information site.
Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images
and in accordance with all technical requirements.
Highlights
Highlights are mandatory for this journal. They consist of a short collection of bullet points that
convey the core findings of the article and should be submitted in a separate editable file in the
online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points
(maximum 85 characters, including spaces, per bullet point). You can view example Highlights on
our information site.
Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and
avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing
with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords
will be used for indexing purposes.
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Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page
of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first
mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.
Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do
not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those
individuals who provided help during the research (e.g., providing language help, writing assistance
or proof reading the article, etc.).
Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy];
the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes
of Peace [grant number aaaa].
It is not necessary to include detailed descriptions on the program or type of grants and awards. When
funding is from a block grant or other resources available to a university, college, or other research
institution, submit the name of the institute or organization that provided the funding.
If no funding has been provided for the research, please include the following sentence:
This research did not receive any specific grant from funding agencies in the public, commercial, or
not-for-profit sectors.
Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If
other units are mentioned, please give their equivalent in SI.
Drug nomenclature
Generic names should be used in text, tables and figures. Trade names and the name and city of their
manufacturer may be mentioned in parentheses in the first text reference to the drug, but should not
appear in titles, figures or tables. Chemical names could also be used. Code numbers could be given
in brackets. When a trade name is used, it should be capitalized; general or chemical names are not
capitalized. The chemical nature of new drugs must be given when known. The form of drug used in
calculations of doses (e.g., base or salt) should be indicated.
Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word
processors build footnotes into the text, and this feature may be used. Should this not be the case,
indicate the position of footnotes in the text and present the footnotes themselves separately at the
end of the article.
Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Indicate per figure if it is a single, 1.5 or 2-column fitting image.
• For Word submissions only, you may still provide figures and their captions, and tables within a
single file at the revision stage.
• Please note that individual figure files larger than 10 MB must be provided in separate source files.
A detailed guide on electronic artwork is available.
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or
convert the images to one of the following formats (note the resolution requirements for line drawings,
halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
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TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi
is required.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
• Supply files that are too low in resolution.
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or
MS Office files) and with the correct resolution. If, together with your accepted article, you submit
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear
in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version. For color reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your accepted article. Please
indicate your preference for color: in print or online only. Further information on the preparation of
electronic artwork.
Figure captions
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure
itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but
explain all symbols and abbreviations used.
Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in
accordance with their appearance in the text and place any table notes below the table body. Be
sparing in the use of tables and ensure that the data presented in them do not duplicate results
described elsewhere in the article. Please avoid using vertical rules and shading in table cells.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice
versa). Any references cited in the abstract must be given in full. Unpublished results and personal
communications are not recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard reference style of the
journal and should include a substitution of the publication date with either 'Unpublished results' or
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted
for publication.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any
further information, if known (DOI, author names, dates, reference to a source publication, etc.),
should also be given. Web references can be listed separately (e.g., after the reference list) under a
different heading if desired, or can be included in the reference list.
Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them
in your text and including a data reference in your Reference List. Data references should include the
following elements: author name(s), dataset title, data repository, version (where available), year,
and global persistent identifier. Add [dataset] immediately before the reference so we can properly
identify it as a data reference. The [dataset] identifier will not appear in your published article.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in
the text) to other articles in the same Special Issue.
Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference
management software products. These include all products that support Citation Style Language
styles, such as Mendeley and Zotero, as well as EndNote. Using the word processor plug-ins from
these products, authors only need to select the appropriate journal template when preparing their
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article, after which citations and bibliographies will be automatically formatted in the journal's style.
If no template is yet available for this journal, please follow the format of the sample references and
citations as shown in this Guide.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following
link:
http://open.mendeley.com/use-citation-style/progress-in-neuropsychopharmacology-and-biological-psychiatry
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-
ins for Microsoft Word or LibreOffice.
Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style
or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book
title, chapter title/article title, year of publication, volume number/book chapter and the pagination
must be present. Use of DOI is highly encouraged. The reference style used by the journal will be
applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted
at proof stage for the author to correct. If you do wish to format the references yourself they should
be arranged according to the following examples:
Reference style
Text: All citations in the text should refer to:
1. Single author: the author's name (without initials, unless there is ambiguity) and the year of
publication;
2. Two authors: both authors' names and the year of publication;
3. Three or more authors: first author's name followed by 'et al.' and the year of publication.
Citations may be made directly (or parenthetically). Groups of references should be listed first
alphabetically, then chronologically.
Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999). Kramer et al.
(2010) have recently shown ....'
List: References should be arranged first alphabetically and then further sorted chronologically if
necessary. More than one reference from the same author(s) in the same year must be identified by
the letters 'a', 'b', 'c', etc., placed after the year of publication.
Examples:
Reference to a journal publication:
Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. J. Sci.
Commun. 163, 51–59.
Reference to a book:
Strunk Jr., W., White, E.B., 2000. The Elements of Style, fourth ed. Longman, New York.
Reference to a chapter in an edited book:
Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S.,
Smith , R.Z. (Eds.), Introduction to the Electronic Age. E-Publishing Inc., New York, pp. 281–304.
Reference to a website:
Cancer Research UK, 1975. Cancer statistics reports for the UK. http://www.cancerresearchuk.org/
aboutcancer/statistics/cancerstatsreport/ (accessed 13 March 2003).
Reference to a dataset:
[dataset] Oguro, M., Imahiro, S., Saito, S., Nakashizuka, T., 2015. Mortality data for Japanese oak
wilt disease and surrounding forest compositions. Mendeley Data, v1. https://doi.org/10.17632/
xwj98nb39r.1.
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.
Video
Elsevier accepts video material and animation sequences to support and enhance your scientific
research. Authors who have video or animation files that they wish to submit with their article are
strongly encouraged to include links to these within the body of the article. This can be done in the
same way as a figure or table by referring to the video or animation content and noting in the body
text where it should be placed. All submitted files should be properly labeled so that they directly
relate to the video file's content. . In order to ensure that your video or animation material is directly
usable, please provide the file in one of our recommended file formats with a preferred maximum
size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in
the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply
'stills' with your files: you can choose any frame from the video or animation or make a separate
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image. These will be used instead of standard icons and will personalize the link to your video data. For
more detailed instructions please visit our video instruction pages. Note: since video and animation
cannot be embedded in the print version of the journal, please provide text for both the electronic
and the print version for the portions of the article that refer to this content.
AudioSlides
The journal encourages authors to create an AudioSlides presentation with their published article.
AudioSlides are brief, webinar-style presentations that are shown next to the online article on
ScienceDirect. This gives authors the opportunity to summarize their research in their own words
and to help readers understand what the paper is about. More information and examples are
available. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides
presentation after acceptance of their paper.
Data visualization
Include interactive data visualizations in your publication and let your readers interact and engage
more closely with your research. Follow the instructions here to find out about available data
visualization options and how to include them with your article.
Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your
article to enhance it. Submitted supplementary items are published exactly as they are received (Excel
or PowerPoint files will appear as such online). Please submit your material together with the article
and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to
supplementary material during any stage of the process, please make sure to provide an updated file.
Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option
in Microsoft Office files as these will appear in the published version.
Research data
This journal encourages and enables you to share data that supports your research publication
where appropriate, and enables you to interlink the data with your published articles. Research data
refers to the results of observations or experimentation that validate research findings. To facilitate
reproducibility and data reuse, this journal also encourages you to share your software, code, models,
algorithms, protocols, methods and other useful materials related to the project.
Below are a number of ways in which you can associate data with your article or make a statement
about the availability of your data when submitting your manuscript. If you are sharing data in one of
these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to
the "References" section for more information about data citation. For more information on depositing,
sharing and using research data and other relevant research materials, visit the research data page.
Data linking
If you have made your research data available in a data repository, you can link your article directly to
the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with
relevant repositories, giving readers access to underlying data that gives them a better understanding
of the research described.
There are different ways to link your datasets to your article. When available, you can directly link
your dataset to your article by providing the relevant information in the submission system. For more
information, visit the database linking page.
For supported data repositories a repository banner will automatically appear next to your published
article on ScienceDirect.
In addition, you can link to relevant data or entities through identifiers within the text of your
manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053;
PDB: 1XFN).
Mendeley Data
This journal supports Mendeley Data, enabling you to deposit any research data (including raw and
processed data, video, code, software, algorithms, protocols, and methods) associated with your
manuscript in a free-to-use, open access repository. During the submission process, after uploading
your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley
Data. The datasets will be listed and directly accessible to readers next to your published article online.
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For more information, visit the Mendeley Data for journals page.
Data in Brief
You have the option of converting any or all parts of your supplementary or additional raw data into
one or multiple data articles, a new kind of article that houses and describes your data. Data articles
ensure that your data is actively reviewed, curated, formatted, indexed, given a DOI and publicly
available to all upon publication. You are encouraged to submit your article for Data in Brief as an
additional item directly alongside the revised version of your manuscript. If your research article is
accepted, your data article will automatically be transferred over to Data in Brief where it will be
editorially reviewed and published in the open access data journal, Data in Brief. Please note an open
access fee of 500 USD is payable for publication in Data in Brief. Full details can be found on the Data
in Brief website. Please use this template to write your Data in Brief.
Data statement
To foster transparency, we encourage you to state the availability of your data in your submission.
This may be a requirement of your funding body or institution. If your data is unavailable to access
or unsuitable to post, you will have the opportunity to indicate why during the submission process,
for example by stating that the research data is confidential. The statement will appear with your
published article on ScienceDirect. For more information, visit the Data Statement page.
AFTER ACCEPTANCE
Online proof correction
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing
annotation and correction of proofs online. The environment is similar to MS Word: in addition to
editing text, you can also comment on figures/tables and answer questions from the Copy Editor.
Web-based proofing provides a faster and less error-prone process by allowing you to directly type
your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions
for proofing will be given in the e-mail we send to authors, including alternative methods to the online
version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this
proof only for checking the typesetting, editing, completeness and correctness of the text, tables and
figures. Significant changes to the article as accepted for publication will only be considered at this
stage with permission from the Editor. It is important to ensure that all corrections are sent back
to us in one communication. Please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility.
Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free
access to the final published version of the article on ScienceDirect. The Share Link can be used
for sharing the article via any communication channel, including email and social media. For an
extra charge, paper offprints can be ordered via the offprint order form which is sent once the
article is accepted for publication. Both corresponding and co-authors may order offprints at any
time via Elsevier's Webshop. Corresponding authors who have published their article open access do
not receive a Share Link as their final published version of the article is available open access on
ScienceDirect and can be shared through the article DOI link.
AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from
Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will
be published.
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